We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01748929
Recruitment Status : Completed
First Posted : December 13, 2012
Last Update Posted : August 29, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
Women of reproductive age are considered a high-risk group for worm infections by the World Health Organization. Maternal infection and anemia contribute to infant malnutrition by affecting milk quality and quantity, and duration of exclusive breastfeeding. To date, no study has investigated the health benefits of postpartum deworming to infants or mothers. A randomized controlled trial will be conducted in Peru to investigate the effectiveness of integrating deworming into routine postpartum care. The primary measure of effect will be infant weight gain between birth and six months of age. Other infant and maternal health indicators will also be ascertained.

Condition or disease Intervention/treatment Phase
Intestinal Diseases, Parasitic Drug: Albendazole Drug: Placebo Phase 4

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1010 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth
Actual Study Start Date : February 24, 2014
Primary Completion Date : February 13, 2015
Study Completion Date : September 16, 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Albendazole
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Albendazole
single dose 400 mg tablet of albendazole
Drug: Albendazole
Placebo Comparator: Placebo
Placebo Manufactured by Hersil Laboratories in Lima, Peru
Drug: Placebo

Outcome Measures

Primary Outcome Measures :
  1. Mean (± standard deviation) weight gain (kg) [ Time Frame: Change between birth and six months of age ]

Secondary Outcome Measures :
  1. Infant morbidity [ Time Frame: 1, 6, 12, 24 months following birth ]
  2. Maternal hemoglobin levels and anemia [ Time Frame: 1, 6, 12, 24 months following birth ]
  3. Breastfeeding practices [ Time Frame: 1, 6, 12, 24 months following birth ]
    The prevalence of current, exclusive, predominant and partial breastfeeding will be used to assess breastfeeding practices. In accordance with WHO criteria, infants will be considered as exclusively breastfed if they ingest only breast milk (excluding vitamins and medications); considered as predominantly breastfed if, in addition to breast milk, they also ingest water, juice, teas, vitamins or medications, and considered as partially breastfed if their primary nutrition source is other than breast milk.

  4. Maternal energy levels [ Time Frame: 1, 6, 12, 24 months following birth ]
    Maternal energy levels will be measured using an adapted 5-item version of the Fatigue Assessment Scale (FAS) (Michielsen et al. 2004). This scale assesses symptoms of physical and cognitive fatigue.

  5. Maternal STH infection [ Time Frame: 1 and 6 months following birth ]
  6. Breast milk quality [ Time Frame: 1 and 6 months following birth ]
    Mean concentrations of key breast milk quality indicators (i.e. macronutrients, immunological factors, vitamins, and minerals) will be used to assess breast milk quality.

  7. Breast milk quantity transferred from mother to infant [ Time Frame: 1 and 6 months following birth ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Deliver at Hospital Iquitos
  • Plan to reside in Iquitos or neighbouring area for the next 24 months
  • Able to communicate in Spanish

Exclusion Criteria:

  • Deliver multiples
  • Delivery a stillborn or an infant with a serious congenital medical condition
  • Transfered to another hospital prior to discharge
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01748929

Asociación Civil Selva Amazónica
Iquitos, Peru
Sponsors and Collaborators
McGill University Health Center
Principal Investigator: Theresa W Gyorkos, PhD McGill University Health Center
Principal Investigator: Martin Casapia, MD, MPH Asociación Civil Selva Amazónica
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr. Theresa Gyorkos, Principal Investigator, McGill University Health Center
ClinicalTrials.gov Identifier: NCT01748929     History of Changes
Other Study ID Numbers: 12-198-GEN
First Posted: December 13, 2012    Key Record Dates
Last Update Posted: August 29, 2017
Last Verified: August 2017

Keywords provided by Dr. Theresa Gyorkos, McGill University Health Center:
Global Health
Soil-Transmitted Helminths
Pregnant Women

Additional relevant MeSH terms:
Intestinal Diseases
Parasitic Diseases
Intestinal Diseases, Parasitic
Gastrointestinal Diseases
Digestive System Diseases
Antiparasitic Agents
Anti-Infective Agents
Anticestodal Agents
Antiplatyhelmintic Agents
Antiprotozoal Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents